Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Comprehensive Analysis of Data from the SEER Registry

被引:22
|
作者
Zhu, Kaixuan [1 ]
Xu, Yingying [2 ]
Fu, Jiaxin [1 ]
Mohamud, Farah Abdidahir [1 ]
Duan, Zongkui [1 ]
Tan, Siyuan [1 ]
Zhao, Zekun [3 ]
Chen, Ping [1 ]
Zong, Liang [1 ]
机构
[1] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Clin Med Coll, Dept Gen Surg, Yangzhou, Jiangsu, Peoples R China
[2] Yangzhou Univ, Yizheng Peoples Hosp, Clin Med Coll, Dept Gen Surg, Yangzhou, Jiangsu, Peoples R China
[3] Tongji Univ, Med Sch, Tongji Hosp, Dept Gen Surg, Shanghai, Peoples R China
关键词
GASTROESOPHAGEAL JUNCTION; GASTRIC CARDIA; CANCER; EPIDEMIOLOGY; ESOPHAGUS; ESOPHAGECTOMY; SURVEILLANCE;
D O I
10.1155/2019/9637972
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background. To determine the ideal surgical approach (total gastrectomy (TG) vs. proximal gastrectomy (PG)) for Siewert type II adenocarcinoma of the esophagogastric junction (AEG), we searched and analyzed the Surveillance, Epidemiology, and End Results (SEER) data. Methods. Patients with Siewert type II AEG treated by TG or PG were identified from the 2004-2014 SEER dataset. We obtained the patients' overall survival (OS) and cancer-specific survival (CSS) and stratified the patients by surgical approach. We performed a propensity score 1 : 1 matching (PSM) analysis and a univariate and multivariate Cox proportional hazards model. Results. A total of 2,217 patients with 6th AJCC stage IA-IIIB Siewert type II AEG was examined: 1,584 patients (71.4%) underwent PG, and 633 patients (28.6%) underwent TG. The follow-up time was 1-131 months. OS favored total gastrectomy before the PSM analysis (chi 2=3.952, p=0.047), but after this analysis, there was no significant difference between TG and PG (chi 2=2.227, p=0.136). The univariate and multivariate analyses identified age as an independent factor, and an X-tail analysis revealed 70 years as a cut-off point. The patients aged >= 70 years obtained a significant long-term OS benefit from PG compared to TG (chi 2=8.245, p=0.004), and those aged<70 years showed no difference between TG and PG (chi 2=0.167, p=0.682). Conclusions. PG showed an equivalent survival benefit to TG in both the early and locally advanced stages of Siewert type II AEG. For elderly patients, PG is strongly recommended because of its clearer OS benefit compared to TG.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] ASO Visual Abstract: Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis
    Kamarajah, Sivesh K.
    Phillips, Alexander W.
    Griffiths, Ewen A.
    Ferri, Lorenzo
    Hofstetter, Wayne L.
    Markar, Sheraz R.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 3) : 517 - 518
  • [32] ASO Visual Abstract: Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis
    Sivesh K. Kamarajah
    Alexander W. Phillips
    Ewen A. Griffiths
    Lorenzo Ferri
    Wayne L. Hofstetter
    Sheraz R. Markar
    Annals of Surgical Oncology, 2021, 28 : 517 - 518
  • [33] Efficacy analysis of Cheng's GIRAFFE reconstruction after proximal gastrectomy for adenocarcinoma of esophagogastric junction
    Zhiyuan Xu
    Can Hu
    Yanqiang Zhang
    Ling Huang
    Litao Yang
    Jianfa Yu
    Pengfei Yu
    Jiahui Chen
    Yian Du
    Xiangdong Cheng
    Chinese Journal of Cancer Research, 2022, 34 (03) : 289 - 297
  • [34] Efficacy analysis of Cheng's GIRAFFE reconstruction after proximal gastrectomy for adenocarcinoma of esophagogastric junction
    Xu, Zhiyuan
    Hu, Can
    Zhang, Yanqiang
    Huang, Ling
    Yang, Litao
    Yu, Jianfa
    Yu, Pengfei
    Chen, Jiahui
    Du, Yian
    Cheng, Xiangdong
    CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (03) : 289 - 297
  • [35] Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction
    Hironobu Goto
    Masanori Tokunaga
    Norihiko Sugisawa
    Yutaka Tanizawa
    Etsuro Bando
    Taiichi Kawamura
    Masahiro Niihara
    Yasuhiro Tsubosa
    Masanori Terashima
    Gastric Cancer, 2013, 16 : 590 - 595
  • [36] Benefit of Neoadjuvant Chemotherapy for Siewert Type II Esophagogastric Junction Adenocarcinoma
    Hosoda, Kei
    Yamashita, Keishi
    Katada, Natsuya
    Moriya, Hiromitsu
    Mieno, Hiroaki
    Sakuramoto, Shinichi
    Kikuchi, Shiro
    Watanabe, Masahiko
    ANTICANCER RESEARCH, 2015, 35 (01) : 419 - 425
  • [37] Siewert type III gastro-oesophageal junction adenocarcinoma; total gastrectomy vs. oesophagectomy
    Walmsley, James
    Browning, Matthew
    Ariyarathenam, Arun
    Berrisford, Richard
    Humphreys, Lee
    Sanders, Grant
    Tham, Ji Chung
    Wheatley, Tim
    Chan, David S. Y.
    BRITISH JOURNAL OF SURGERY, 2023, 110
  • [38] Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction
    Goto, Hironobu
    Tokunaga, Masanori
    Sugisawa, Norihiko
    Tanizawa, Yutaka
    Bando, Etsuro
    Kawamura, Taiichi
    Niihara, Masahiro
    Tsubosa, Yasuhiro
    Terashima, Masanori
    GASTRIC CANCER, 2013, 16 (04) : 590 - 595
  • [39] Phase I Clinical Research of Jejunal Interposition in Adenocarcinoma of the Esophagogastric Junction II/III Proximal Gastrectomy
    Tao, Kai
    Dong, Jian-Hong
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2016, 2016
  • [40] Risk factors for anastomotic leakage after gastrectomy for Siewert type II/III adenocarcinoma of the esophagogastric junction: a retrospective case-control study
    Li Yibo
    Shi Yinan
    You Jun
    Hu Wenqing
    Xu Yingying
    Wei Haotang
    Abe Masanobu
    Cheng Jiajia
    Zong Liang
    Dong Jianhong
    生物组学研究杂志(英文), 2021, 04 (02) : 71 - 76